Payment overview · 2025
General Payments
$13,453.14
303 reported records · 30 companies
Healthcare provider profile · identity verified
Daniel D. Cabello, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CLEARWATER, FL · NPI 1730196965
Verified facts
What the public records show
CMS Open Payments records show Daniel D. Cabello, M.D. received $13,453.14 in general payments during 2025 across 303 reported records.
SK Life Science, Inc. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Epidiolex, Fintepla, Fycompa, Nayzilam, Nurtec Odt, Qulipta, Sunosi, Ubrelvy, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ubrelvy by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Sunosi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZONISADE as an associated drug or biological on 537 records involving 321 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zonisade by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Fycompa by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Epidiolex by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 31 records involving 31 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Invega Sustenna by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fintepla as an associated drug or biological on 12923 records involving 3741 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Fintepla by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$7,281.59 | 54.1% | 21 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $948.15 | 7.0% | 40 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $743.14 | 5.5% | 39 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $674.11 | 5.0% | 24 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $368.01 | 2.7% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $356.94 | 2.6% | 22 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $356.10 | 2.6% | 17 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $295.84 | 2.2% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $271.17 | 2.0% | 10 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$206.33 | 1.5% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $185.44 | 1.4% | 13 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $184.10 | 1.4% | 9 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $180.63 | 1.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $164.61 | 1.2% | 7 | 2025 |
| NEUROPACE, INC. | Unresolved — no canonical attribution shown | $156.46 | 1.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $154.83 | 1.1% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $140.01 | 1.0% | 10 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $124.51 | 0.9% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $114.20 | 0.8% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $98.92 | 0.7% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $96.49 | 0.7% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.65 | 0.5% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.32 | 0.4% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $52.51 | 0.4% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $51.79 | 0.4% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $44.02 | 0.3% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $28.68 | 0.2% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.03 | 0.2% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $19.82 | 0.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $13.74 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,762.80 | 298 |
| Honoraria | $5,600.00 | 1 |
| Travel and Lodging | $1,090.34 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $6,982.84 | 10 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $489.81 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $462.40 | 23 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $426.87 | 20 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $423.47 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $356.94 | 22 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $356.10 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $303.98 | 19 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $295.84 | 11 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $280.79 | 11 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $250.64 | 10 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $249.43 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $242.05 | 13 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $222.87 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $220.77 | 13 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $206.33 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $180.63 | 10 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $178.41 | 8 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $164.61 | 7 | 2025 |
Source payment records
|
|||||
| RNS Neurostimulator Kit Normalized: rns neurostimulator kit |
Device | NEUROPACE, INC. | $156.46 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $140.01 | 10 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $124.51 | 4 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $114.20 | 5 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $103.75 | 5 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $100.66 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $99.94 | 5 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $96.49 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $85.50 | 8 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $77.75 | 5 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $74.52 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $63.65 | 3 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $57.06 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $55.32 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $52.51 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $51.79 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $28.68 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 109 | exact normalized | Medicare Part D |
| Fintepla fintepla |
2025 | Fintepla | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 105 | exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 49 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 178 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ZONISADE open payments reported associated product |
CMS Open Payments — General Payments 537 supporting records · 321 recipient NPIs · example record 1242666894 |
Zonisade · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
105 | 13 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
109 | 13 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 31 supporting records · 31 recipient NPIs · example record 1174584421 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
178 | 20 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Fintepla open payments reported associated product |
CMS Open Payments — General Payments 12923 supporting records · 3741 recipient NPIs · example record 1224348643 |
Fintepla · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
49 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 579 | 133 |
| Lamotrigine | Lamotrigine | 365 | 70 |
| Levetiracetam Er | Levetiracetam | 288 | 74 |
| Lacosamide | Lacosamide | 263 | 38 |
| Clonazepam | Clonazepam | 240 | 46 |
| Oxcarbazepine | Oxcarbazepine | 207 | 38 |
| Xcopri | Cenobamate | 178 | 20 |
| Divalproex Sodium Er | Divalproex Sodium | 177 | 37 |
| Lamotrigine Er | Lamotrigine | 170 | 28 |
| Topiramate | Topiramate | 168 | 42 |
| Gabapentin | Gabapentin | 148 | 36 |
| Memantine Hcl | Memantine Hcl | 141 | 42 |
| Donepezil Hcl | Donepezil Hcl | 129 | 42 |
| Aptiom | Eslicarbazepine Acetate | 123 | 12 |
| Pregabalin | Pregabalin | 118 | 19 |
| Divalproex Sodium | Divalproex Sodium | 116 | 19 |
| Zonisamide | Zonisamide | 115 | 30 |
| Lorazepam | Lorazepam | 112 | 23 |
| Diazepam | Diazepam | 109 | 22 |
| Epidiolex | Cannabidiol (Cbd) | 109 | 13 |
| Fycompa | Perampanel | 105 | 13 |
| Alprazolam | Alprazolam | 73 | 11 |
| Clobazam | Clobazam | 70 | suppressed |
| Temazepam | Temazepam | 65 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 16 |
| Briviact | Brivaracetam | 59 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Nayzilam | Midazolam | 49 | 20 |
| Primidone | Primidone | 46 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 11 |
| Qulipta | Atogepant | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 41 | 13 |
| Dilantin | Phenytoin Sodium Extended | 38 | suppressed |
| Phenobarbital | Phenobarbital | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Lamictal | Lamotrigine | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Belsomra | Suvorexant | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Sunosi | Solriamfetol Hcl | 27 | suppressed |
| Lamictal Xr | Lamotrigine | 26 | suppressed |
| Rufinamide | Rufinamide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Onfi | Clobazam | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Ubrelvy | Ubrogepant | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Fintepla | Fenfluramine Hcl | 19 | suppressed |
| Topiramate Er | Topiramate | 18 | suppressed |
| Dayvigo | Lemborexant | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Armodafinil | Armodafinil | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Felbamate | Felbamate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Zonisade | Zonisamide | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Depakote Er | Divalproex Sodium | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Lunesta | Eszopiclone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,453.14 · 303 records | SK Life Science, Inc. | ACTHAR, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, DAYBUE, ELYXYB - CELECOXIB, EPIDIOLEX, FYCOMPA, Fintepla, Gocovri, HORIZANT, INBRIJA, INGREZZA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, ONGENTYS, Ocrevus Zunovo, PONVORY, PRECIVITYAD2, QULIPTA, Qelbree, REXULTI, RNS Neurostimulator Kit, Sunosi, Symbravo, TRUDHESA, UBRELVY, VALTOCO, VRAYLAR, VYALEV, VYEPTI, VYVGART HYTRULO, WAKIX, XCOPRI, XYWAV, Xeomin, ZAVZPRET, ZTLido, Zilbrysq | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error